Rapport Therapeutics, Inc. (RAPP) Dividend History

Company News

• Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

  Rapport Therapeutics announced that its Phase 2a trial of RAP-219 for refractory focal epilepsy is fully enrolled and on track to report topline results in September 2025. The company also provided updates on the RAP-219 development program and its financial position.

  GlobeNewswire Inc.
• Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

  Rapport Therapeutics, a clinical-stage biotechnology company, announced two encore poster presentations at the 2025 AAN Annual Meeting. The presentations will highlight the company's ongoing research and development of RAP-219, a clinical-stage AMPA receptor negative allosteric modulator, for the treatment of refractory focal epilepsy.

  GlobeNewswire Inc.
• Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

  Rapport Therapeutics announced positive results from its Phase 1 trials for RAP-219, a potential treatment for central nervous system disorders. The data showed that RAP-219 achieved target receptor occupancy and was generally well-tolerated, supporting its ongoing Phase 2a trial in focal epilepsy.

  GlobeNewswire Inc.
• Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences

  Rapport Therapeutics, a clinical-stage biotechnology company, announced that it will present on its lead product candidate RAP-219 at two upcoming medical conferences focused on epilepsy. The presentations will cover the novel design of a Phase 2a proof-of-concept trial for RAP-219 in patients with drug-resistant focal epilepsy, as well as the underlying mechanism of action.

  GlobeNewswire Inc.
• Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit

  Rapport Therapeutics, a clinical-stage biotechnology company, announced that it will present at the Morgan Stanley Global Healthcare Conference and the TD Cowen's Novel Mechanisms in Neuropsychiatry Summit. The company is focused on developing small molecule medicines for central nervous system disorders.

  GlobeNewswire Inc.